Trial Profile
A Phase II, Trial of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Myeloma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Chloroquine (Primary) ; Cyclophosphamide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 14 Feb 2018 Status has been changed to discontinued.
- 16 Jun 2014 Planned End Date changed from 1 Oct 2016 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 16 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.